Collection to commercialization: Is standardization the bottleneck or breakthrough for cell and gene therapy?

Prepare not only for today’s requirements, but also for the expectations that will define the future of cell therapy development.

Cell therapy developers face a growing challenge in scaling programs to meet global trial complexity while satisfying increasingly urgent demands from investors and regulators. Investors want evidence of commercial readiness from the earliest stages, while regulators are signaling a heightened focus on standardization across multi-site trials. Together, these pressures are reshaping the way therapeutic sponsors and service providers must plan their programs.

In this panel discussion, leaders from across the cell therapy ecosystem will share perspectives on how to anticipate these pressures and build strategies that set programs up for long-term success.

We’ll explore:

• The challenges sponsors face in managing global trials and the importance of forward-looking planning
• How investor and regulatory priorities are influencing development decisions earlier than ever before
• The role of integrated, standardized supply chain solutions in reducing variability and supporting compliance